EXOZYMES INC.

eXoZymes Inc. (Nasdaq: EXOZ) is a development-stage biomanufacturing company focused on creating sustainable chemical production solutions through its proprietary exozyme technology platform. The company's website is www.exozymes.com.

eXoZymes develops AI-designed and engineered enzymes called exozymes that function in cell-free bioreactors outside of living cells to produce valuable chemicals including active pharmaceutical ingredients, nutraceuticals, and biofuels. The company's core technology represents a departure from traditional synthetic biology approaches by eliminating the complexity and scalability challenges associated with engineering living cells. Instead, eXoZymes isolates and stabilizes desired enzymes in controlled bioreactor environments, enabling multi-step chemical conversions with high yields, purity, and efficiency while operating under benign aqueous conditions.

The company's commercialization strategy focuses initially on low-volume, high-value compounds positioned as nutraceuticals with potential pharmaceutical applications. This approach allows faster time-to-market with lower regulatory complexity while establishing a foundation for future pharmaceutical development. eXoZymes is developing N-trans-Caffeoyltyramine (NCT), a naturally occurring small molecule targeting metabolic pathways related to obesity, diabetes, and fatty liver disease, as its lead program through a subsidiary called NCTX. The company has also received significant government funding for isobutanol production for sustainable aviation fuel applications.

eXoZymes employs a partnership-focused business model utilizing spin-outs, joint ventures, and licensing arrangements to commercialize its biosolutions. The company has received approximately $17.7 million in research and development grants from the U.S. Department of Energy, National Institutes of Health, Gates Foundation, and Shell since inception through December 2025. The company maintains intellectual property protection through a portfolio of patents and patent applications, including an exclusive license from the Regents of the University of California covering cofactor regeneration and cannabinoid biosynthesis technologies.

As a pre-revenue development-stage company, eXoZymes operates as a platform technology provider seeking to demonstrate asset value through successful commercialization of its exozyme-based biomanufacturing solutions across multiple markets and applications.